Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 1 / Phase 2INTERVENTIONAL

NPI-002 Intravitreal Implant for the Delay of Cataract Progression

Safety and Efficacy of NPI-002 Intravitreal Implant for the Delay of Cataract Progression in Patients Undergoing Vitrectomy

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study will examine the safety and efficacy NPI-002 intravitreal implants post vitrectomy.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Indicated for vitrectomy 2. Natural Lens in place at time of vitrectomy 3. Some cataract present as assessed pre-operatively Who Should NOT Join This Trial: 1. Previous intraocular surgery in study eye. 2. Clear zonular weakness or defects / coloboma. 3. Not on stable dose of medications for other conditions. 4. Need for oral corticosteroids during study participation. 5. Evidence or history of uveitis, or ocular ischemia. 6. Current smoker 7. Use of supplemental oxygen 8. Evidence or history of proliferative diabetic retinopathy. 9. Current lung disease (PU, COPD, Asthma) resulting in decreased oxygen saturation. 10. Sensitivity to thiol compounds. 11. Participation in another clinical trial. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Indicated for vitrectomy 2. Natural Lens in place at time of vitrectomy 3. Some cataract present as assessed pre-operatively Exclusion Criteria: 1. Previous intraocular surgery in study eye. 2. Clear zonular weakness or defects / coloboma. 3. Not on stable dose of medications for other conditions. 4. Need for oral corticosteroids during study participation. 5. Evidence or history of uveitis, or ocular ischemia. 6. Current smoker 7. Use of supplemental oxygen 8. Evidence or history of proliferative diabetic retinopathy. 9. Current lung disease (PU, COPD, Asthma) resulting in decreased oxygen saturation. 10. Sensitivity to thiol compounds. 11. Participation in another clinical trial.

Treatments Being Tested

DRUG

NPI-002 Intravitreal Implant

Implant inserted during vitrectomy.

Locations (1)

Royal Adelaide Hospital
Adelaide, Australia